1 / 3

Pulmonary Arterial Hypertension (PAH) Market

The global pulmonary arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025. <br>

tom_clark
Download Presentation

Pulmonary Arterial Hypertension (PAH) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pulmonary Arterial Hypertension (PAH) Market Revenue Drivers Growth Opportunities Supply Chain Analysis and Forecast Research Report Till 2025 “The global pulmonary arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025.” The global Pulmonary Arterial Hypertension (PAH) Market research report provides complete insights on industry scope, trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development. Market Overview: The global pulmonary arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Key Players: Actelion Pharmaceuticals, Ltd Gilead Sciences, Inc United Therapeutics Corporation Novartis International AG GlaxoSmithKline Plc. (GSK) Pfizer Dong-A ST Co., Ltd. Merck Sharp & Dohme Corp Bayer HealthCare

  2. Request free sample to get complete analysis of top-performing companies @ https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah- market/request-sample Growth Drivers: The market for PAH is growing moderately due to newer launches of pipeline drugs that target different pathways to suppress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment. Globally the PAH market is segmented on the basis of Drug class, Surgery, and region. On the basis of Drug class, the global PAH market is classified into Endothelin Receptor Antagonists (ERAs) (Tracleer, Opsumit, Letairis)- These medications reverse the effect of endothelin, a substance in the walls of blood vessels that causes them to narrow; Prostacyclin and Prostacyclin Analogs- were the first medications approved by the U.S. FDA for the treatment of PAH. Phosphodiesterase-5 (PDE-5) V Inhibitors, Sildenafil, and Tadalafil- Revatio, Viagra, Cialis, etc. These drugs work by opening the blood vessels in the lungs to allow blood to flow easily. These drugs have superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and side-effects. Global PAH Drug Class Outlook: Prostacyclin and Prostacyclin Analogs SGC Stimulators ERA PDE-5 On the basis of surgeries, the global PAH market is classified into Atrial Septostomy- This is an open heart surgery; in which surgeon will create an opening between the upper left and right chambers of your heart to relieve the pressure on the right side of heart. Transplantation- Lung or heart-lung transplant might be an option especially for younger people who have idiopathic pulmonary arterial hypertension. Regional Outlook: Geographically, PAH market is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and Rest of the World. North America held the maximum share of market for PAH in terms of revenue in 2013, which is then followed by Europe. These two developed regions are expected to witness substantial growth during the forecast period, due to the recently approved PAH drugs in the market and the products that are anticipated to receive approval during the next few years. In the Asia Pacific region, Japan, China, India, Australia, and New Zealand exhibit immense opportunities for the companies operating in the PAH market. The low level of awareness regarding the diagnosis and treatment of PAH is one of the prime reasons restraining the market growth in MEA and rest of the world. The patent expirations of major PAH drugs along with the availability of generic drugs are expected to adversely affect the overall revenue of the market. Browse Related Category Research Reports @ https://blog.naver.com/tomclark

  3. Get in touch At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions. Contact Person: Ryan Manuel Research Support Specialist, USA Email: ryan@millioninsights.com Asia Pacific Global Headquarters Million Insights Million Insights Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016 India Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States Phone: 1-408-610-2300 Email: sales@millioninsights.com Phone: 91-20-65300184 Email: sales@millioninsights.com

More Related